DDInter1397 DDInter286
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression.
Paroxetine {u} (Compound) binds {v} (Gene) SLC6A4
SLC6A4 {u} (Gene) is bound by {v} (Compound) Dexfenfluramine
Dexfenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Caplacizumab
Paroxetine {u} (Compound) downregulates {v} (Gene) TIMM9
TIMM9 {u} (Gene) is downregulated by {v} (Compound) Dexfenfluramine
Dexfenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Caplacizumab
Paroxetine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Levomilnacipran
Levomilnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Caplacizumab
Paroxetine {u} (Compound) downregulates {v} (Gene) PFN1
PFN1 {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Dasatinib {u} may lead to a major life threatening interaction when taken with {v} Caplacizumab
Paroxetine {u} (Compound) downregulates {v} (Gene) PFN1
PFN1 {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Ponatinib {u} may lead to a major life threatening interaction when taken with {v} Caplacizumab
Paroxetine {u} (Compound) causes {v} (Side Effect) Bursitis
Bursitis {u} (Side Effect) is caused by {v} (Compound) Sibutramine
Sibutramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Caplacizumab
Paroxetine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Ticlopidine
Ticlopidine {u} may lead to a major life threatening interaction when taken with {v} Caplacizumab
Paroxetine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Ponatinib
Ponatinib {u} may lead to a major life threatening interaction when taken with {v} Caplacizumab
Paroxetine {u} (Compound) causes {v} (Side Effect) Thirst
Thirst {u} (Side Effect) is caused by {v} (Compound) Levomilnacipran
Levomilnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Caplacizumab
Paroxetine {u} (Compound) causes {v} (Side Effect) Hernia
Hernia {u} (Side Effect) is caused by {v} (Compound) Clopidogrel
Clopidogrel {u} may lead to a major life threatening interaction when taken with {v} Caplacizumab
Paroxetine (Compound) binds SLC6A4 (Gene) and SLC6A4 (Gene) is bound by Dexfenfluramine (Compound) and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab
Paroxetine (Compound) downregulates TIMM9 (Gene) and TIMM9 (Gene) is downregulated by Dexfenfluramine (Compound) and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab
Paroxetine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Levomilnacipran (Compound) and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab
Paroxetine (Compound) downregulates PFN1 (Gene) and PFN1 (Gene) is downregulated by Dasatinib (Compound) and Dasatinib may lead to a major life threatening interaction when taken with Caplacizumab
Paroxetine (Compound) downregulates PFN1 (Gene) and PFN1 (Gene) is downregulated by Ponatinib (Compound) and Ponatinib may lead to a major life threatening interaction when taken with Caplacizumab
Paroxetine (Compound) causes Bursitis (Side Effect) and Bursitis (Side Effect) is caused by Sibutramine (Compound) and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab
Paroxetine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Ticlopidine (Compound) and Ticlopidine may lead to a major life threatening interaction when taken with Caplacizumab
Paroxetine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Ponatinib (Compound) and Ponatinib may lead to a major life threatening interaction when taken with Caplacizumab
Paroxetine (Compound) causes Thirst (Side Effect) and Thirst (Side Effect) is caused by Levomilnacipran (Compound) and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab
Paroxetine (Compound) causes Hernia (Side Effect) and Hernia (Side Effect) is caused by Clopidogrel (Compound) and Clopidogrel may lead to a major life threatening interaction when taken with Caplacizumab